ArticleMicrosystems & nanoengineering2026
Biostable wireless sensor-integrated bioresorbable stent for real-time monitoring of vascular pressure and fractional flow reserve.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Stent implantation is widely used to treat coronary artery disease, yet in-stent restenosis (ISR) remains a major clinical challenge. Fractional flow reserve (FFR) is the gold-standard index for evaluating restenosis severity, but current techniques are invasive and unsuitable for continuous monitoring. Here, we present a bioresorbable smart stent platform that enables real-time intravascular pressure sensing and continuous FFR monitoring. The system integrates a MEMS-based LC pressure sensor, fabricated from SU-8 and gold, onto a hybrid 3D-printed vascular stent composed of polycaprolactone (PCL) and polylactic acid (PLA). Structural refinements and an optimized fabrication process enable long-term sensor reliability, minimize signal drift, and maintain stable resonance frequency. Across 100 fabricated devices, the pressure sensors show a resonance frequency of 82.2 ± 1.7 MHz and a sensitivity of 37.48 ± 2.13 kHz/mmHg. In vitro closed-loop fluidic tests using a vascular phantom confirmed the stable, wireless operation of the device and its ability to accurately assess hemodynamic parameters. The dual-sensor configuration enables simultaneous upstream and downstream pressure measurements, yielding FFR values that closely match those from a commercial system (R² = 0.97) under varying stenosis severities. The proposed smart stent offers a promising pathway toward long-term, non-invasive vascular monitoring and early detection of ISR.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.